Myeloproliferative neoplasms (MPN) are haematological diseases, characterized by clonal hematopoiesis. Hemostasis abnormalities are among the most critical and frequent complications, affecting the quality of life and a possible reason for death. Thrombotic complications are common and multifactorial. Our aim was to study some genetic thrombophilia factors -Factor V Leiden (FVL), G20210A mutation in prothrombin gene (PR G20210A) and PLA2 allele polymorphism of glycoprotein IIIa gene (GPIIIa gene), and their frequency and association with thrombotic risk in both Philadelphia-positive and Philadelphia-negative MPN -chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary and PLA2 allele polymorphism of GPIIIa gene proved to be the complications -26.85% of our patients were carriers, and 24.14% of them reported thrombotic complications.
Introduction
Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoiesis, originating from stem cells. They are characterized by the accumulation of cells of different cell lines in the bone marrow, peripheral blood and spleen, as well as in other organs, that are prone to terminal differentiation [1] . The term covers chronic polycythemia vera (PV), essential thrombocythemia (ET), as well as some rare conditions like chronic eosinophilic leukaemia, mastocytosis and others [2] .
These conditions are divided into two main on Philadelphia chromosome carrier -from intracellular and intercellular signal pathways hyperactivation. An essential step in CML pathogenesis is the presence of the Philadelphia chromosome, leading to BCR-ABL fusion gene formation. It produces a continuously active protein that activates molecular cascade, accelerating cell division. In Philadelphia-negative MPN (PV, ET and MF) JAK-STAT signal pathway plays a primary role -a point mutation JAK2 V617F (9p24) leads to increased signals, independent of physiological stimuli, from the cell surface receptors to the nucleus.
Hemostasis disorders in Philadelphianegative MPN are one of the main pathogenic mechanisms, leading to late complications and even death [1] . Hemostasis is of the procoagulant type. Thrombotic complications are not that carrier is slightly studied [3] [4] [5] [6] .
Thrombosis pathogenesis includes different Inherited and acquired thrombophilia and others [7] . Thrombophilia is the predisposition to venous and arterial thrombosis. Inherited and acquired conditions may cause abnormal coagulation. Amongst the essential thrombophilia genetic factors as a cause for Factor V Leiden (FVL) -point mutation that leads to activated protein C inability to recognize its factor V binding place. This results in uncontrolled prothrombin G20210A mutation in the prothrombin gene (PR G20210A) that leads to prothrombin factor on the platelet surface. Carrier of this mutation is associated with increased platelet aggregation [8] [9] [10] and thrombosis risk.
physiological hemostasis through different FVL -a point mutation, where guanine is replaced by adenine at nucleotide 1691, leading to the formation of glutamine instead of arginine at amino acid 506 in factor V amino acid chain. It is one of the three binding points for activated protein C to factor V heavy chain. Activated factor V is a cofactor in the prothrombinase complex, leading to the formation of thrombin. Activated protein C degrades factor VIIIa.
In the presence of this point mutation, the abnormal factor V is resistant to proteolytic inactivation of activated protein C, and protein S. FVL remains procoagulant and Moreover, FVL is an abnormal cofactor for activated protein C when degrading factor inhibitor is also activated, leading to inhibitor, and this explains why the thrombus PR G20210A -a substitution of guanine with adenine at 20210 nucleotide of the prothrombin gene. Thrombin plays a central role in physiological hemostasis. It leads to activates other coagulation factors and platelets. Prothrombin is increased when this mutation is present. The exact thrombogenic GPIIIa gene -this platelet receptor for activation and is formed by two subunits platelet aggregation. Polymorphism is a point mutation, in which cytosine is replaced by thymidine in exon 2, phenotypically leading to the replacement of proline with leucine in 33 position of GPIIIa [11, 12] . Different guidelines present recommendations for patient testing when thrombophilia carriership status is suspected [13] [14] [15] . Knowledge about many factors may be necessary for the prognosis and therapy optimization -genetic thrombophilia, JAK2
comorbidities. We aimed to study the role of some genetic thrombophilia factors (FVL, PR G20210A, and of MPN patients. An objective of this article was to determine the frequency of genetic thrombophilia carriership status in MPN patients (isolated and combined) and compare it with the control group. We also aimed to determine the carriership frequency in patients with thrombotic complications with or without a family history, and patients without such complications. Another objective was to investigate the association between thrombophilia carriership status and thrombosis risk.
Materials and Methods
We used selective screening to determine MPN patients. Informed consent was obtained from all patients, as well as information about passport data, disease history and treatment, comorbidities (myocardial infarction, ischemic heart disease, arterial hypertension, heart failure, diabetes, obesity, hyperlipidemia, liver conditions, and neoplasms). Special attention was paid to questions about thrombotic complications before and after diagnosis, family history and most common thrombosis provoking factors -surgery, trauma, prolonged immobilization, malignancies, hormone therapy, and smoking. In women, we inquired about spontaneous abortions and pregnancy complications. Seven to ten millilitres of venous blood was obtained.
We performed deoxyribonucleic acid (DNA) extraction. Genomic DNA extraction from peripheral blood leucocytes was performed using the AccuPrepR Genomic DNA Extraction Kit (Bioneer, South Korea), according to the manufacturer's instructions, or by the salting-out method. Spectrophotometric analysis was used to determine the purity and the concentration of 
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Results
Thrombophilia FVL carriership status
We found 104 (96.30%) non-carriers and 4 (3.70%) FVL carriers (all heterozygous) - Figure 1 . The carriers were 2 patients with PV, and 2 patients with CML. No thrombotic complications were registered in these patients. The frequency found in the control group was (4.76%) FVL carriers (all heterozygous).
PR G20210A carriership status
We found that 100 (92.59%) of our patients were non-carriers and 8 (7.41%) were heterozygous carriers. In the control group, 144 patients (97.96%), and 3 patients (2.04%) were heterozygous carriers (Figure 2 ). Chi-square Of the patients we investigated, two of the 8 PR G20210A carriers had a thrombotic complication, and there were no complications in the three control group carriers. RR 2.2222 (p=0.576), OR 2.0588 (p=0.666).
GPIIIa gene
We found 79 (73.15%) non-carriers, four (3.70%) homozygous carriers, and 25 (23.15%) heterozygous carriers, whereas in the control group there were 134 (91.16%) non-carriers, one (0.68%) homozygous and 12 (8.16%) heterozygous (Figure 3 ). Total mutation carriership in our patients was 26 
Combined carriership status
We found 3 (2.78%) patients with combined carriership -two of them were G20210A and . Only one patient reported a thrombotic event. These data could not be conclusive.
Thrombotic events
Twenty-seven (25.00%) of our patients reported a past thrombotic event before diagnosed. Fifteen (13.89%) patients reported thrombotic ischemic brain attacks, 8 (7.41%) -deep vein thrombosis, and 2 (1.85%) -spleen infarction.
Thirty (27.78%) of our patients reported thrombotic event before or after diagnosis, and 12 (40.00%) of them -both. Eight of these 30 patients were found with thrombophilia mutations (Chi 0.357, p=0.550, OR 1.442, RR 1.319).
In 38 (35.19% of all patients) patients, we found thrombophilia carriership, and 8 (21.05%) of them reported thrombosis.
Discussion
FVL is an autosomal-dominant disease. It is reported to increase the risk of thrombosis 5-10 times in heterozygous carriers, and 50-100 times -in homozygous ones (as compared to non-carriers) [20] [21] [22] . The usual frequency of FVL is 2-15%, and up to 40% in patients with thrombotic complication [11, [23] [24] [25] . We did not [27, 28] and have emphasized on the fact that FVL carriership was associated with higher thrombosis relapse rate [28] . Other authors have reported data similar thrombotic complications in FVL carriers with MPN diagnosis [29] .
Prothrombin mutation (G20210A) is found in 1-2% of the population and up to 20% in patients with thrombosis [29, 30] . According to literature data, heterozygous carriers are exposed to 3-5 times higher thrombotic risk [21, 22, 30, 32, 33] . The total mutation frequency in our patients was 7.41% (8 out of 108 patients -all heterozygous) and 2.04% in control group (3 out of 147 healthy controls -all heterozygous), p = 0.037 (95% CI, 0.1402-12.0397, Chi 4.332).
2.2222 (p=0.576), OR 2.0588 (p=0.666). This a higher thrombotic risk among MPN patients with prothrombin mutation carriership [34] .
Although GPIIIa polymorphism proved to between its carriership and thrombotic risk [35] .
importance for coronary heart disease risk [36] , but little data is published on its prevalence in MPN patients and contribution to thrombosis in these populations [29] . According to our results, frequent in our patients than in the control group. Of 29 GPIIIa carriers, 7 thrombotic complications were registered while in the control group no thrombosis was found in 13 carriers. RR 7.0000, OR 9.0000. Among GPIIIa carriers, 7 thrombotic events were registered in 108 patients (6.48%). These 7 patients represented 25.93% of all 27 MPN patients with thrombotic events. It was previously reported that PV patients with GPIIIa had increased thrombotic risk [29] .
Most of the studies available on thrombophilia and thrombotic risk include patients, diagnosed with PV and ET, rarely MF and CML or all four of these.
Conclusions
Thrombophilic disorders play a role in thrombotic complications pathogenesis in MPN patients. necessary on all possible risk factors, and their multifactorial pathogenesis. This would lower the risk of a common and dangerous complication correlation between FVL and G20210A polymorphisms and increased thrombotic risk in MPN patients. Currently, few study reports exist on GPIIIa relation to thrombotic complications. In our patient population, this polymorphism number of patients, as well as patients being prospectively investigated for yet unrevealed
